Purpose: Asthma is characterized by chronic type 2/eosinophilic inflammation in the airway mucosa. This study aimed to explore the clinical value of 2 cutoffs of blood eosinophil counts (≥ 300/μL and ≥ 150/μL) in eosinophilic asthma, with relation to eosinophilderived neurotoxin (EDN), a surrogate marker of eosinophilic activity. Methods: To compare clinical features and eosinophil-related mediators according to 2 cutoffs of peripheral blood eosinophil counts (≥ 300/μL and ≥ 150/μL), 137 adult asthmatics who had maintained antiasthmatic medications, including inhaled corticosteroid and long-acting beta 2 agonist, without biologics, were enrolled. EDN levels in serum, urine and sputum were measured by enzymelinked immunosorbent assay. Results: Patients with asthma and higher blood eosinophil counts ( ≥ 300/μL) had a higher prevalence of severe asthma, chronic rhinosinusitis, partly controlled/uncontrolled status, and higher levels of sputum eosinophils and EDN in serum/sputum than those with lower blood eosinophil counts (< 300/μL). When compared between patients with asthma having higher blood eosinophils ( ≥ 150/μL) and those with lower eosinophils ( < 150/μL), there were no differences in symptom severity, control status or lung function parameters. Conclusion These findings suggest that blood eosinophil count ≥ 300/μL may identify asthma patients at higher risk for severity and heightened eosinophil activity, supporting its utility as a biomarker in a real clinical setting.

Background: Rosacea is a chronic inflammatory skin disorder characterized by erythema, papules, ocular symptoms, and heightened sensitivity. Patients with neurogenic symptoms such as burning or stinging remain particularly difficult to manage. Current guidelines often underrepresent energy-based devices (EBDs), pigmentary sequelae, psychosocial burden, and ocular comorbidities. Objective: To examine Korean dermatologists’ expert perspectives on rosacea management, focusing on skin sensitivity, neurogenic symptoms, pigmentary changes, psychosocial impact, ocular involvement, and EBD use. Methods: A web-based, 29-item survey was administered to 25 board-certified Korean dermatologists (May–June 2025). Quantitative and qualitative responses were analyzed. Results: Erythematotelangiectatic and papulopustular phenotypes with sensitivity skin predominated. EBDs (pulsed dye laser, intense pulsed light) were frequently used but limited by cost and sensitivity issues. Neurogenic symptoms were recognized but rarely treated with neuromodulators. Post-inflammatory hyperpigmentation was infrequent, yet monitoring was inconsistent.Psychosocial and ocular aspects were acknowledged but seldomly systematically addressed.Respondents expressed interest in emerging adjunctive treatments such as cold plasma, skin boosters, and holistic care approaches. Conclusion Korean dermatologists adopt individualized strategies for rosacea, yet practice gaps remain regarding neurogenic symptoms, pigmentary complications, and psychosocial and ocular comorbidities. Findings support the need for updated multidisciplinary, phenotype-driven guidelines aligned with real-world practice.

Background: Many smart care technologies have been developed recently, but it remains unclear which of them are necessary for use in long-term care hospitals (LTCHs). Methods: A total of 114 physicians, registered nurses (RNs), nurse assistants (NAs), and care assistants (CAs) from eight LTCHs completed a survey assessing perceived needs for 10 smart care technologies using 5-point Likert scales. One-sample t-tests, one-way ANOVA with Scheffé post-hoc tests, Friedman tests, and simple linear regression were used to examine differences by occupation and hospital characteristics. Additionally, focus group interviews with 10 participants were done. Results: Mean perceived need for smart care technologies was 3.99, with the highest ratings for smart mattresses (4.14), all-in-one patient transfer robots (4.09), and smart monitoring systems (4.06). Regarding the most preferred by occupation, physicians chose smart monitoring systems (4.19) and leg-care devices (4.19), RNs chose smart mattresses (4.11), NAs chose radar-based fall detection devices (4.22), and CAs chose all-in-one patient transport robots (4.36). Perceived need for smart care technologies was higher in LTCHs with lower monthly family fees and in those without a rehabilitation service, explaining 42.8% and 10.8% of the variability, respectively. Conclusion Smart care technologies were seen as necessary in LTCHs, but the types of technologies considered most important differed by occupational role and hospital characteristics.

Background: Older patients aged ≥75 years are underrepresented in major statin trials, leaving the optimal statin intensity after acute ischemic stroke (AIS) undefined. We aimed to compare functional outcomes and short-term safety between high-intensity statin therapy (HIST) and moderate-intensity statin therapy (MIST) in patients aged ≥75 years with AIS or transient ischemic attack. Methods: Using a prospective stroke registry at a single tertiary center (2019–2022), we retrospectively analyzed 337 patients aged ≥75 years with AIS or transient ischemic attack who maintained statin therapy for 3 months (HIST n=117; MIST n=220). The primary outcome was a favorable 3-month functional outcome (modified Rankin Scale score 0–2). Secondary outcomes included stroke recurrence, adverse effects, and statin discontinuation. Multivariable logistic regression with pre-specified sensitivity analyses was performed. Results: Favorable outcomes at 3 months were more frequent with HIST (70.9% vs. 55.9%; p=0.010). After multivariable adjustment, HIST was independently associated with a favorable outcome (adjusted odds ratio [aOR]=2.03, 95% confidence interval [CI] 1.17–3.53), consistent across sensitivity analyses: per-protocol (aOR=3.48, 95% CI 1.97–6.17) and atrial fibrillation-adjusted (aOR=2.21, 95% CI 1.26–3.89). No significant differences were observed in statin discontinuation, stroke recurrence, or adverse effects. Conclusion In older patients with AIS, HIST was independently associated with better functional outcomes without evidence of increased harm, broadly consistent with current guideline recommendations for HIST when tolerated. Prospective studies are needed to confirm a causal relationship.

Background: Alzheimer’s disease is more prevalent among females. Estrogens influence brain metabolism and function, and low blood levels before, during, and after menopause may be associated with cognitive decline in later years. Here, we investigate the association between hormone therapy and reproductive lifespan with cognitive performance using a nationally representative sample from the National Health and Nutrition Examination Survey (NHANES) database. Methods: This cross-sectional study included 1,374 eligible women aged 60 years or older from the NHANES database. Cognitive performance was assessed using the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) word learning subtest, the Animal Fluency Test (AFT), and the Digit Symbol Substitution Test (DSST). Univariate analysis and multivariate logistic regression were employed to evaluate the association between hormone therapy, reproductive span, and cognitive performance. Restricted cubic spline curves were used to assess the relationship between age as a continuous variable and cognitive performance. Results: After adjusting for age, race, and educational level, hormone therapy was significantly associated with word recall, digit symbol, and animal fluency cognitive performance (p < 0.05). The reproductive span was associated with word recall performance (p = 0.027) but not with digit symbol or animal fluency. The age-related cognitive decline is attenuated by hormone therapy with maximum effect between 65 and 70 years for all dimensions. Conclusion There is a positive association between hormone therapy and cognitive performance in postmenopausal women, particularly in age groups with the steeper decline. In addition, there is no significant association between reproductive span and cognitive function.

Persistent idiopathic dentoalveolar pain (PIDAP) is a chronic orofacial pain condition characterized by persistent pain in the absence of detectable dental pathology. Due to its ambiguous clinical presentation, PIDAP is frequently overlooked or misdiagnosed, leading to prolonged patient suffering and unnecessary dental treatments. This review provides a structured educational overview of PIDAP for dental students and early-career clinicians, covering its definition, taxonomy, differential diagnosis, pathophysiology, clinical significance, and management principles. A narrative literature review was conducted using PubMed and Scopus databases with the following search terms: “persistent dentoalveolar pain,” “atypical odontalgia,” “PIDAP,” “orofacial pain,” and “chronic overlapping pain conditions.” The search covered publications up to December 2024, limited to English-language articles. Priority was given to relevant classification guidelines, epidemiological data, and studies addressing diagnostic challenges, nomenclature changes, pathophysiology, and the relationship between PIDAP and chronic overlapping pain conditions (COPCs). Thirty-four key references were included after screening. Current diagnostic criteria, the historical evolution of PIDAP taxonomy, and major pathophysiological hypotheses—including peripheral sensitization, central sensitization, and nociplastic pain mechanisms—are summarized. The high rate of comorbidity with COPCs and the frequent misdiagnosis of PIDAP highlight its clinical importance, as epidemiological data indicate that diagnostic delays may range from several months to years. Improving awareness and understanding of PIDAP among dental students and clinicians can facilitate early recognition, reduce misdiagnosis, and contribute to more effective management. Incorporating PIDAP-related education into undergraduate dental curricula and continuing education programs may further bridge current knowledge gaps and improve patient outcomes.

Background: Mice are useful small animal models to study the pathogenesis of SARS-CoV-2 infection. As the ancestral SARS-CoV-2 strains did not utilize murine Ace2 as a receptor, wild-type mice were not susceptible to the SARS-CoV-2 infection. Infection of human ACE2-expressing transgenic mice with SARS-CoV-2 induces fatal encephalitis, which is not commonly observed in humans. We and others have previously demonstrated the ability of the SARS-CoV-2 Beta variant to productively infect wild-type mice. Herein, we employed RNA-seq to investigate the transcriptomic landscapes in the lungs after the infection of wild-type mice with SARS-CoV-2 Beta variant. Methods: We intranasally infected 6-week-old wild-type C57BL/6J mice with the SARS-CoV-2 (B.1.351 strain) and collected lungs at 3- and 6-days post-infection for RNA-sequencing. We used the Limma-Voom package to identify differentially expressed genes (DEGs) and the fgsea package for pathway enrichment analysis. We used Cytoscape to identify hub genes and gene networks. Lastly, we employed RT-qPCR and multiplex assay to validate the RNA-seq data. Results: Using a cutoff of an adjusted p-value below 0.05 and an absolute log2 fold change value greater than 0.75, we identified 285 DEGs on day 3 and 46 DEGs on day 6. The canonical pathways analysis showed that several key pathways such as apoptosis and cytokine response were upregulated in the infected lungs. Protein-protein interaction analyses identified innovative target genes such as if11, Ccna2, and Aurkb. We also identified the top 10 hub genes that included Prc1, Ube2c, Ccnb2, Ncapg, Aurkb, Cep55, Mki67, Dlgap5, Ccna2, and Kif11. RT-qPCR analysis for Tnfa, Il6, Ccl2, and Ccl3 further validated the RNA-seq analysis. Consistent with gene expression results, we detected significantly increased protein levels of various inflammatory mediators such as IL-6, CCL2, CXCL2, and CXCL10 in the infected lungs. Conclusions This is the first transcriptomic analysis of the lungs of wild-type mice infected with a clinical isolate of SARS-CoV-2. Our findings provide a further understanding of the pathogenic events that occur in this mouse model of SARS-CoV-2 infection.

Methods: A total of 31 C5 motor palsies in 26 patients were included in this case series. Patients underwent 16 anterior cervical discectomy and fusions, six laminoplasties, and four laminectomies with fusion procedures. Visual Analog Scale (VAS) pain scores, Neck Disability Index (NDI), and strength scores were recorded during pre- and postoperative follow-up visits. Statistical analysis was conducted using Fisher’s exact test and a paired t-test with analysis of variance. Results: The mean preoperative motor strength grades for the deltoid and biceps were 2.1 and 3.2, respectively. At final follow-up, mean deltoid and bicep motor grades had significantly improved compared to preoperative values (p <0.0001, p <0.0001, respectively). Significant improvements were also observed in NDI scores (39.3 to 26.7, p <0.05) and VAS pain scores (4.42 to 2, p <0.05) at final follow-up. Conclusions This study is the first to report outcomes of surgical management for spontaneous, de novo C5 motor palsies. Following surgical intervention, patients experienced favorable recovery of deltoid and bicep motor strength. Both anterior and posterior approaches resulted in successful motor recovery when appropriately selected based on preoperative imaging and surgical planning.

Chrysoeriol, a flavonoid naturally found in several plants, including Danggui Susan, a traditional herbal medicine, exhibits promising anti-inflammatory and antioxidant properties. Its potential to prevent cardiovascular diseases, primarily through inhibiting platelet activation and aggregation, has attracted significant interest. This study aimed to investigate the molecular mechanisms underlying the antiplatelet effects of chrysoeriol. The compound effectively suppressed collagen-induced platelet aggregation without inducing cytotoxicity. Chrysoeriol elevated intracellular levels of cyclic AMP (cAMP) and cyclic GMP (cGMP), enhanced inositol 1,4,5-trisphosphate receptor (IP 3R) phosphorylation, and reduced cytosolic calcium (Ca2+ ) mobilization, all of which contributed to its antiplatelet action. Furthermore, chrysoeriol inhibited the phosphorylation of PI3K, Akt, JNK, and p38 MAPK, pathways involved in the activation of cytosolic phospholipase A2 (cPLA 2) and thromboxane A2 (TXA2) production. These effects were accompanied by reduced TXA2 production and secretion of dense granules (ATP and serotonin). Chrysoeriol also impaired thrombin-induced clot retraction, further suggesting its capacity to regulate platelet responses and cytoskeletal rearrangements. These findings highlight chrysoeriol’s multi-target mechanisms, including modulation of cyclic nucleotides, kinase pathways, and platelet function, offering potential as a therapeutic agent to prevent thrombotic cardiovascular events.